Monopar Therapeutics (MNPR) Income towards Parent Company: 2017-2019
Historic Income towards Parent Company for Monopar Therapeutics (MNPR) over the last 3 years, with Dec 2019 value amounting to -$1.2 million.
- Monopar Therapeutics' Income towards Parent Company fell 32.23% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.3 million, marking a year-over-year decrease of 36.88%. This contributed to the annual value of -$4.3 million for FY2019, which is 31.04% down from last year.
- Per Monopar Therapeutics' latest filing, its Income towards Parent Company stood at -$1.2 million for Q4 2019, which was down 61.29% from -$759,448 recorded in Q3 2019.
- Over the past 5 years, Monopar Therapeutics' Income towards Parent Company peaked at -$373,839 during Q1 2017, and registered a low of -$14.9 million during Q3 2017.
- For the 3-year period, Monopar Therapeutics' Income towards Parent Company averaged around -$2.0 million, with its median value being -$828,354 (2018).
- Data for Monopar Therapeutics' Income towards Parent Company shows a peak YoY increase of 95.52% (in 2018) and a maximum YoY decrease of 140.01% (in 2018) over the last 5 years.
- Quarterly analysis of 3 years shows Monopar Therapeutics' Income towards Parent Company stood at -$736,800 in 2017, then fell by 25.73% to -$926,358 in 2018, then tumbled by 32.23% to -$1.2 million in 2019.
- Its Income towards Parent Company was -$1.2 million in Q4 2019, compared to -$759,448 in Q3 2019 and -$932,109 in Q2 2019.